Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Liraglutide vs Orforglipron: Liraglutide has the stronger overall evidence (7.5 vs 5.5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Liraglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Liraglutide and Orforglipron have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-titrated, subcutaneous once daily. Diabetes (Victoza): escalate 0.6 → 1.2 → 1.8 mg/day. Weight management (Saxenda): escalate weekly to 3.0 mg/day. DO NOT self-dose.
any
Subcutaneous once-daily injection (Victoza for diabetes, Saxenda for weight)
INVESTIGATIONAL — no approved consumer dose. In trials, once-daily oral orforglipron was titrated up to 36 mg (some phase-2 cohorts to 45 mg) with gradual dose escalation to limit GI side effects. Not for self-administration; only appropriate within a clinical trial or, if/when approved, under a prescribing clinician.
any
Oral tablet (investigational)
Weeks to months
Months (titrated over weeks)
Months to years
Especially during dose escalation
Weeks to months
Months (titrated)
Throughout use
Especially during dose escalation
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER).
N Engl J Med (2016) · Rct · n=9340
Double-blind cardiovascular-outcomes RCT: 9,340 patients with type 2 diabetes and high cardiovascular risk, liraglutide (up to 1.8 mg/day) vs placebo, median follow-up 3.8 years
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes).
N Engl J Med (2015) · Rct · n=3731
56-week double-blind RCT in 3,731 adults WITHOUT type 2 diabetes (BMI ≥30, or ≥27 with comorbidities), liraglutide 3.0 mg/day vs placebo plus lifestyle (2:1)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
JAMA (2015) · Rct · n=846
56-week double-blind RCT in 846 adults with overweight/obesity AND type 2 diabetes, liraglutide 3.0 mg vs 1.8 mg vs placebo (2:1:1)
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1).
N Engl J Med (2025) · Rct · n=3127
Phase-3 multinational double-blind RCT in 3,127 adults with obesity WITHOUT diabetes; once-daily oral orforglipron 6/12/36 mg vs placebo for 72 weeks
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1).
N Engl J Med (2025) · Rct · n=559
Phase-3 double-blind RCT in 559 adults with early type 2 diabetes managed by diet/exercise; once-daily oral orforglipron 3/12/36 mg vs placebo for 40 weeks
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Lancet (2026) · Rct · n=962
Phase-3 non-inferiority RCT (n=962) in type 2 diabetes inadequately controlled on metformin; once-daily oral orforglipron 3/12/36 mg vs dapagliflozin 10 mg over 40 weeks
Liraglutide has a higher evidence score (7.5/10 vs 5.5/10) and wins in 2 of 3 categories.
For manage blood sugar, Liraglutide has a higher relevance score (80 vs 70).
No known interactions between Liraglutide and Orforglipron have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.